Bharat Biotech Limited today announced to ramp up manufacturing capacity for its COVID-19 vaccine, Covaxin, by additional 200 million doses which will be produced at its Gujarat-based subsidiary unit.
In an official statement, the company claimed that the production capacity has been increased at Chiron Behring Vaccines, a wholly-owned subsidiary of Bharat Biotech located in Gujarat’s Ankleshwar.
“The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on inactivated vero cell platform technology,” it added.
The production availability at the Ankleshwar-based manufacturing plant will commence from fourth quarter of 2021, Bharat Biotech claimed.
Comments are closed.